Omalizumab has an anti-inflammatory effect on cellular markers in both blood and nasal tissues of patients with seasonal allergic rhinitis. Swedish researchers investigated its effect on changes in inflammatory cell numbers in nasal biopsy specimens from patients with seasonal allergic rhinitis.
They report omalizumab binds to circulating immunoglobin E (IgE) to prevent induction of the allergic process. The investigators, from Sahlgrenska University Hospital in Goteborg, University Hospital in Umea and Orebro University hospital, randomised participants to omalizumab or placebo before pollen season.
Treatment continued during the season. Symptoms and medication use were recorded, blood samples and nasal biopsy specimens were obtained before and during the season.
The researchers say blood eosinophils increased in placebo patients during the season but not in omalizumab patients; the difference was significant.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!